Back to Trial

Oracle Runs

Oracle findings and outcome history for A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer (NCT07051486).

Runs
3
Findings
3
Latest Run
Apr 6, 2026, 2:08 PM
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)

Will the results be positive?

NCT07051486 is recruiting with primary completion in Feb 2026. No results posted on ClinicalTrials.gov or sponsor releases for this exact trial. Related phase 2 data (NCT05896020) in HER2+ gynecologic cancers (incl. cervical subset, ORR 63.6%) described as encouraging, but this is a separate dedicated trial. Evidence is incomplete and not trial-specific.

Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:19 PM
ClinicalTrialsclinicaltrials.gov
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Current status: Recruiting. Estimated primary completion: 2026-02-01. Single-arm Phase 2 in patients with HER2-expressing recurrent/metastatic cervical cancer who failed prior therapy. Primary endpoint: ORR by IRC. No results posted.
Web Searchascopubs.orgMay 28, 2025, 12:00 AM
SHR-A1811 in patients (pts) with HER2-expressing advanced gynecological cancers (Gynecol C): A phase 2 study
Separate trial (NCT05896020). In 35 cervical cancer pts, ORR 63.6%, PFS 10.7 mo. Conclusions: encouraging activity and manageable safety in HER2-expressing advanced Gynecol C (includes OC/EC/CC). Not specific to NCT07051486.
NO_DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public efficacy readout was found. The cited ClinicalTrials.gov record still shows this Phase 2 study as recruiting with “No Results Posted,” and the sponsor’s item describes first-patient-in only and ongoing recruitment rather than outcome data.

Found Apr 3, 2026, 4:04 PMReviewed Apr 3, 2026, 4:47 PM
ClinicalTrialsclinicaltrials.govNov 17, 2025, 12:00 AM
Study Details | NCT07051486 | A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
ClinicalTrials.gov lists NCT07051486 as Recruiting, estimated primary completion 2026-02, and explicitly shows “No Results Posted.”
Sponsorhengrui.comJul 20, 2023, 12:00 AM
Hengrui Pharma: First patient enrolled in Phase II study of SHR-A1811 for HER2-expressing gynecologic malignancies
Sponsor news says the Phase II gynecologic malignancy study completed first patient enrollment and was recruiting nationally; it does not report efficacy outcomes for the cervical trial.
NO_DECISIONDismissed98% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

No trial-specific public efficacy readout was found. The ClinicalTrials.gov record for NCT07051486 shows the study is still recruiting, with estimated primary completion in February 2026, and the record indicates no results posted. That is insufficient to label the trial positive or negative.

Found Apr 1, 2026, 6:48 PMReviewed Apr 1, 2026, 7:04 PM
ClinicalTrialsclinicaltrials.govNov 17, 2025, 12:00 AM
Study Details | NCT07051486 | A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
ClinicalTrials.gov lists NCT07051486 as Recruiting, with estimated primary completion in 2026-02, and the page shows “No Results Posted Record History.”
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

No oracle outcome history is available for this trial yet.